TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39535462

Group type: EXPERIMENTAL
Intervention: Tozorakimab 60 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tozorakimab 300 mg
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tozorakimab 600 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 39535568

Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Vagus somatosensory evoked potentials (VSEP)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Known risk factors (ApoE4 risk alleles, dysosmia, poor cognitive performance)
Number of subjects: 604
Study: 39535661

Group type: EXPERIMENTAL
Intervention: Cipaglucosidase alfa plus miglustat (cipa+mig)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alglucosidase alfa plus placebo (alg+pbo)
Number of subjects: 100
Study: 39535683

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 1615
Study: 39535685

Group type: EXPERIMENTAL
Intervention: IXE/IXE (continuous treatment)
Number of subjects: 289

Group type: COMPARATOR
Intervention: IXE/PBO (interrupted treatment)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: IXE/PBO + IXEQ4W (retreatment after relapse)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: IXE (continuous treatment)
Number of subjects: 289
Study: 39535768

Group type: EXPERIMENTAL
Intervention: Symptom screening with symptom feedback and management care pathways
Number of subjects: 445

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 445
Study: 39535812

Group type: EXPERIMENTAL
Intervention: Symptom screening with SSPedi (daily for 5 days)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Symptom screening with SSPedi
Number of subjects: 345

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 345
Study: 39535868

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39535875

Group type: EXPERIMENTAL
Intervention: Neurology-based collaborative care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 39536019

Group type: EXPERIMENTAL
Intervention: Home-based active tDCS (HB-a-tDCS) on the left dorsolateral prefrontal cortex (l-DLPFC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Home-based sham tDCS (HB-s-tDCS) on the primary motor cortex (M1)
Number of subjects: 48
Study: 39536026

Group type: EXPERIMENTAL
Intervention: Multimodal stress reduction and lifestyle modification program
Number of subjects: 19
Study: 39536238

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses combined)
Number of subjects: 2539
Study: 39536246

Group type: EXPERIMENTAL
Intervention: Antioxidant supplements
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no antioxidant supplements)
Number of subjects: 48
Study: 39536397

Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (soy-protein-based, high-monounsaturated-fatty-acid, multi-fiber) as milk replacement for breakfast and an extra meal after dinner.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (individualized dietary counseling only).
Number of subjects: 112
Study: 39536433

Group type: EXPERIMENTAL
Intervention: CDK 4/6 inhibitors (CDK 4-6i)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Endocrine sensitive subgroup
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Secondary endocrine resistant subgroup
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Primary endocrine resistant subset
Number of subjects: 701

Group type: COMPARATOR
Intervention: Capecitabine (second-line treatment)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Taxane-based chemotherapy (second-line treatment)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Everolimus plus exemestane (second-line treatment)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Fulvestrant (second-line treatment)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Second-line treatments (overall)
Number of subjects: 701
Study: 39536455

Group type: EXPERIMENTAL
Intervention: Ad26/protein preF RSV vaccine
Number of subjects: 1118
Study: 39536477

Group type: EXPERIMENTAL
Intervention: 3-antigen HBV vaccine (3-A-HBV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-antigen HBV vaccine (1-A-HBV)
Number of subjects: 0
Study: 39536691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 39536751

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum-based chemotherapy
Number of subjects: 15
Study: 39536780

Group type: EXPERIMENTAL
Intervention: HIFES and Sync RF+ treatment (single 20-min treatment on the submental area)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 8
Study: 39536846

Group type: EXPERIMENTAL
Intervention: Self-expanding THV
Number of subjects: 759

Group type: COMPARATOR
Intervention: Balloon-expandable THV
Number of subjects: 759
Study: 39536847

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Number of subjects: 2801

Group type: COMPARATOR
Intervention: Aspirin alone in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Dual/single antiplatelet therapy in patients with elevated hsCRP
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 2801
Study: 39536860

Group type: EXPERIMENTAL
Intervention: Tiered parenting programs (universal, targeted/universal, secondary/tertiary, tertiary)
Number of subjects: 878
Study: 39537191

Group type: EXPERIMENTAL
Intervention: Genotype-guided de-escalation strategy (switching from ticagrelor/prasugrel to clopidogrel)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel)
Number of subjects: 1000
Study: 39537385

Group type: EXPERIMENTAL
Intervention: Drug-free group (both GC and HCQ withdrawal)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: HCQ group (discontinued GC but maintained HCQ)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Dual maintenance group (both GC and HCQ continued)
Number of subjects: 333
Study: 39537438

Group type: EXPERIMENTAL
Intervention: MRI-guided SBRT
Number of subjects: 100

Group type: COMPARATOR
Intervention: CT-guided SBRT
Number of subjects: 100
Study: 39537648

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 25
Study: 39537876

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Physical activity and exercise programs
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Advanced training for palliative care
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: CRF guidelines awareness
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Medical training improvements
Number of subjects: 148
Study: 39537877

Group type: EXPERIMENTAL
Intervention: Pre-symptomatic scintigraphic imaging cascade screening
Number of subjects: 100
Study: 39537976

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 1065
Study: 39538001

Group type: EXPERIMENTAL
Intervention: Avacincaptad pegol (ACP) 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 39538073

Group type: EXPERIMENTAL
Intervention: Standardized implementation evaluation of EBIs
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Involvement of policy makers and establishment of psychosocial care in insurance systems
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sharing evidence to increase awareness
Number of subjects: 31
Study: 39538139

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (various classes including thiazide diuretics, ACE inhibitors, ARBs, calcium channel blockers)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Guideline-based antihypertensive therapy
Number of subjects: 311
Study: 39538176

Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg orally once daily
Number of subjects: 321
Study: 39538192

Group type: EXPERIMENTAL
Intervention: Expanded CDS-triggering system offering kidney-specific advice
Number of subjects: 66

Group type: COMPARATOR
Intervention: Current CDS-triggering system
Number of subjects: 66
Study: 39538216

Group type: EXPERIMENTAL
Intervention: Shen-based Qigong Exercise (SBQE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: SBQE vs Control
Number of subjects: 40
Study: 39538234

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 109
Study: 39538259

Group type: EXPERIMENTAL
Intervention: 3-fraction regimen (9 Gy per fraction)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 5-fraction regimen (7 Gy per fraction)
Number of subjects: 162
Study: 39538278

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 300

Group type: COMPARATOR
Intervention: Electrocautery dissection
Number of subjects: 300
Study: 39538331

Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine administered via electroporation, three doses encoding an average of 11 neoantigens per patient (range 4-20).
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Number of subjects: 18
Study: 39539144

Group type: EXPERIMENTAL
Intervention: Triazavirin (TZV) 250 mg capsules three-times daily for 7 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Oseltamivir 75 mg capsules twice per day for 7 days
Number of subjects: 2
Study: 39539489

Group type: EXPERIMENTAL
Intervention: Early endoscopy (within 12 hours after admission)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Delayed endoscopy (within 12-24 hours after admission)
Number of subjects: 368
Study: 39539491

Group type: EXPERIMENTAL
Intervention: Neurofeedback augmented mindfulness training (NAMT)
Number of subjects: 31
Study: 39539565

Group type: EXPERIMENTAL
Intervention: Aquablation therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 116
Study: 39539569

Group type: EXPERIMENTAL
Intervention: Fully immersive virtual reality cognitive training (fi-VRCT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 39539664

Group type: EXPERIMENTAL
Intervention: Anticoagulant monotherapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Combination therapy with anticoagulants and antiplatelet agents
Number of subjects: 400
Study: 39539687

Group type: EXPERIMENTAL
Intervention: OSTRC-H2-SLO (translated version of the OSTRC-H2)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: OSTRC-H2-SLO
Number of subjects: 188
Study: 39540041

Group type: EXPERIMENTAL
Intervention: Physiological model-based decision support system (DSS) advice
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard care without DSS advice
Number of subjects: 95
Study: 39540187

Group type: EXPERIMENTAL
Intervention: MIND + SOUL brain healthy diet intervention
Number of subjects: 29
Study: 39540275

Group type: EXPERIMENTAL
Intervention: Left ventricular unipolar voltage mapping
Number of subjects: 29
Study: 39540300

Group type: EXPERIMENTAL
Intervention: Women with prior preeclampsia
Number of subjects: 679

Group type: COMPARATOR
Intervention: Women from the general population (controls)
Number of subjects: 679
Study: 39540322

Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 0
Study: 39540459

Group type: EXPERIMENTAL
Intervention: My Grief app (based on cognitive-behavioural therapy)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Waitlist control group (no access to the My Grief app)
Number of subjects: 248
Study: 39540661

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg/day on days 1-14, 25 mg/day afterward) plus nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sunitinib plus nivolumab
Number of subjects: 40
Study: 39540734

Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 10 mg/kg daily (maximum 372 mg; equivalent to 5.4 mg/kg or 200 mg isavuconazole) for up to 84 days (IA) or 180 days (IM)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 10 mg/kg daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Simulated doses of 15 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 31
Study: 39540799

Group type: EXPERIMENTAL
Intervention: TDF starting at gestational week 16 with HBV vaccinations for the infant
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard care: TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant
Number of subjects: 280
Study: 39540820

Group type: EXPERIMENTAL
Intervention: AI-QCPA (HeartFlow)
Number of subjects: 33

Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 33
Study: 39540934

Group type: EXPERIMENTAL
Intervention: safinamide 100 mg/day after 2 weeks of 50 mg/day
Number of subjects: 199
Study: 39541094

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 39541169

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg daily for 16 weeks
Number of subjects: 12
Study: 39541202

Group type: EXPERIMENTAL
Intervention: Toripalimab plus etoposide and platinum-based chemotherapy (EP)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo plus etoposide and platinum-based chemotherapy (EP)
Number of subjects: 442
Study: 39541340

Group type: EXPERIMENTAL
Intervention: Mobile health intervention (mHealth) in addition to existing healthcare practices
Number of subjects: 764

Group type: COMPARATOR
Intervention: Control group adhering to current healthcare practices
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Mobile health intervention (mHealth)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Having a live newborn
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Previous experience with contraceptive initiation
Number of subjects: 764
Study: 39541363

Group type: EXPERIMENTAL
Intervention: Training workshop + hands-on sessions + smoker referral competition + award presentation ceremony
Number of subjects: 184

Group type: COMPARATOR
Intervention: 3-hour training workshop (control group)
Number of subjects: 184
Study: 39541377

Group type: EXPERIMENTAL
Intervention: Tumor analysis
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Positive SDHA and SDHB staining combined with negative CA9 labeling
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Plasma succinate levels above 4.94µM
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Circulating miR-483-5p
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Sum of dinucleotide methylation rate of TERT promoter CpGs above 42%
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Biomarker combinations
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Combining biomarkers with clinical data
Number of subjects: 231
Study: 39541403

Group type: EXPERIMENTAL
Intervention: Cisplatin treatment
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (plasma)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (urine)
Number of subjects: 154
Study: 39541522

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study: 39541537

Group type: EXPERIMENTAL
Intervention: Double-well potential model (DWPM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DWPM
Number of subjects: 0
Study: 39541551

Group type: EXPERIMENTAL
Intervention: Symptomatic intracerebral hemorrhage (sICH) defined by SITS-MOST criteria
Number of subjects: 4370

Group type: EXPERIMENTAL
Intervention: Asymptomatic intracerebral hemorrhage (aICH) defined by SITS-MOST criteria
Number of subjects: 4370
Study: 39541755

Group type: EXPERIMENTAL
Intervention: L test
Number of subjects: 34
Study: 39541838

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention (watching a video with virtual reality glasses)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no virtual reality intervention)
Number of subjects: 82
Study: 39541993

Group type: EXPERIMENTAL
Intervention: Geriatrician-led multidisciplinary comprehensive geriatric assessment (CGA)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Geriatrician-led multidisciplinary CGA
Number of subjects: 228
Study: 39542091

Group type: EXPERIMENTAL
Intervention: McGrath Mac video laryngoscope
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Standard Macintosh laryngoscope
Number of subjects: 2600
Study: 39542133

Group type: EXPERIMENTAL
Intervention: Group videoconference intervention (VCI) + standard of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control (AC) + standard of care
Number of subjects: 0
Study: 39542219

Group type: EXPERIMENTAL
Intervention: Hypertensive disorders of pregnancy (HDP)
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Small-for-gestational-age (SGA) infants
Number of subjects: 954
Study: 39542469

Group type: EXPERIMENTAL
Intervention: Bankart repair + remplissage
Number of subjects: 114

Group type: COMPARATOR
Intervention: Latarjet procedure
Number of subjects: 114
Study: 39542473

Group type: EXPERIMENTAL
Intervention: NTDT-PRO T/W domain
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: NTDT-PRO SoB domain
Number of subjects: 145

Group type: COMPARATOR
Intervention: T/W domain
Number of subjects: 145

Group type: COMPARATOR
Intervention: SoB domain
Number of subjects: 145
Study: 39542488

Group type: EXPERIMENTAL
Intervention: Women with hypertension (HTN)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Men with hypertension (HTN)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Women with diabetes
Number of subjects: 314

Group type: COMPARATOR
Intervention: Men with diabetes
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Women who are tobacco users
Number of subjects: 314

Group type: COMPARATOR
Intervention: Men who are tobacco users
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Women who are smokers
Number of subjects: 314

Group type: COMPARATOR
Intervention: Men who are smokers
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Women with BMI ≥30 kg/m²
Number of subjects: 314

Group type: COMPARATOR
Intervention: Men with BMI ≥30 kg/m²
Number of subjects: 314
Study: 39542489

Group type: EXPERIMENTAL
Intervention: Goal-directed mobilisation (GDM) during hospitalisation, which includes personal goal setting and a short session of patient education through a physiotherapist.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 162
Study: 39542642

Group type: COMPARATOR
Intervention: US-TAP block
Number of subjects: 340

Group type: COMPARATOR
Intervention: L-TAP block
Number of subjects: 340
Study: 39542655

Group type: EXPERIMENTAL
Intervention: Combined paclitaxel and chemokine modulatory regimen (CKM) including rintatolimod, IFN-α2b, and celecoxib
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined paclitaxel and CKM regimen
Number of subjects: 9
Study: 39542948

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 160
Study: 39542995

Group type: EXPERIMENTAL
Intervention: Sovateltide (0.3 µg/kg) administered intravenously in three doses at 3 ± 1 h intervals on Days 1, 3, and 6.
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (saline).
Number of subjects: 158
Study: 39543001

Group type: EXPERIMENTAL
Intervention: 300-mg BUP-XR injection in the upper arm
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 300-mg BUP-XR injection in the thigh
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 300-mg BUP-XR injection in the buttocks
Number of subjects: 88

Group type: COMPARATOR
Intervention: 300-mg BUP-XR injection in the abdomen (reference)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Safety evaluations including treatment-emergent adverse events and assessments of injection site pain, tenderness, erythema, induration, and swelling
Number of subjects: 88
Study: 39543185

Group type: EXPERIMENTAL
Intervention: Culturally tailored anti-smoking messages
Number of subjects: 966

Group type: COMPARATOR
Intervention: Non-tailored messages
Number of subjects: 966
Study: 39543304

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) group (n=34) - 8-week program, three sessions per week, supplemented by an educational class once per week.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Educational (EDU) group (n=20) - attended an educational class once per week and encouraged to perform moderate-to-vigorous physical activity on their own.
Number of subjects: 54
Study: 39543340

Group type: EXPERIMENTAL
Intervention: NEIVATECH system (9 hours of therapy, 18 half-hour sessions over 1 month)
Number of subjects: 0
Study: 39543502

Group type: EXPERIMENTAL
Intervention: Implementation of a Learning Health Care Network (LHCN) across early psychosis programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of measurement-based care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 0
Study: 39543515

Group type: EXPERIMENTAL
Intervention: GOAL! program (Combined Lifestyle Intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 50
Study: 39543521

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Hydrocortisone exposure
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Multidimensional assessment of functional outcomes
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Telephone questionnaires
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: In-person study visit
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry
Number of subjects: 800
Study: 39543527

Group type: EXPERIMENTAL
Intervention: ABOi-RAKT
Number of subjects: 239

Group type: COMPARATOR
Intervention: ABOi-OKT
Number of subjects: 239
Study: 39543578

Group type: EXPERIMENTAL
Intervention: Mini-screws with a rough, titanium oxide-coated surface
Number of subjects: 16
Study: 39543590

Group type: EXPERIMENTAL
Intervention: Geometric-based identification method
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Superimposition method
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sex determination function
Number of subjects: 23